Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

NCT03847519 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-Small Cell
Metastatic Squamous Cell Carcinoma
Metastatic Non-Squamous Cell Carcinoma

Interventions

DRUG: ADXS-503
DRUG: Pembrolizumab

Sponsor

Advaxis, Inc.